Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00432575 | Efficacy and Safety of Surinabant Treatment as an Aid to Smoking Cessation (SURSMOKE) | PHASE2 | COMPLETED | 810 | — | — | Jan 1, 2007 | Apr 1, 2008 | Apr 15, 2009 | 8 | Belgium, France +6 |
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | - |
| 2 | ACTIVE_COMPARATOR | surinabant 2,5 mg/day |
| 3 | ACTIVE_COMPARATOR | surinabant 5 mg/day |
| 4 | ACTIVE_COMPARATOR | surinabant 10 mg/day |
| Name | Type | Description |
|---|---|---|
| surinabant (SR147778) | DRUG | oral administration |
| placebo | DRUG | oral administration |
Inclusion Criteria: * Patients over legal age smoking at least 10 cigarettes/day as a mean within the 6 months preceding the screening visit. Exclusion Criteria: * Patients with a limited level of motivation. * Other participant in a household enrolled in the study. * Patients who have smoked or ...